Yale Cancer Center (YCC) is one of only 56 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.
Gene Expression Testing Varies Substantially by Region for Prostate Cancer
December 10, 2020 — Despite gene expression tests helping health care professionals make optimal treatment decisions, testing varies by region for men with prostate cancer and could be related to socioeconomic status and patterns of prostate cancer care.
Dr. Petrylak on the Results of the EV-103 Trial in Bladder Cancer
May 1st 2020Daniel P. Petrylak, MD, professor of medicine and urology, co-leader, Cancer Signaling Networks, Yale Cancer Center, and 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the results of the phase 1b/2 EV-103 trial in bladder cancer.
High PD-L1 Expression, bTMB Effective Markers for Single-Agent Atezolizumab Benefit in NSCLC
December 29th 2019PD-L1-high status, determined via 3 separate immunohistochemistry assays, and blood tumor mutational burden strongly favored atezolizumab over platinum-based chemotherapy and supports the PD-L1 inhibitor as a first-line treatment option in patients with advanced non–small cell lung cancer.